Abstract: Objectives: To compare the efficacy, reasons for discontinuation and continuation rates of the etonogestrel (ENG)-subdermal contraceptive implant when offered at no cost, and the basis of free choice versus short-acting reversible contraceptive (SARC) methods including combined oral contraceptives (COCs), once-a-month injectables, vaginal ring, and patch.
Methods: We conducted a prospective study at the University of Campinas, Brazil, involving women aged 18 to 40 years. They were counseled on various contraceptive methods before entering the study and followed up every 3 months for up to 24 months. Satisfaction was assessed using a Likert scale. Survival rates were estimated using the Kaplan-Meier test, and curve comparisons were performed using the log-rank test.
Results: We enrolled 609 women including 358/609 women (58.8%) who chose the ENG-implant and 251/609 (41.2%) who chose SARC methods. Contraceptive failure and all other reasons for discontinuation were significantly higher in SARC users compared to the ENG-implant users (P < 0.001 and P = 0.002, respectively). The continuation rate was higher among ENG-implant users (89.9% and 75.4%) compared to SARC methods users (27.2% and 15.9%) up to 1 and 2 years after study initiation, respectively. Satisfaction was high in both groups (>82%).
Conclusions: The ENG-implant showed higher contraceptive effectiveness and higher continuation rates than SARC methods up to 2 years after study initiation. Furthermore, users from both groups were highly satisfied with their contraceptive. The main reason for discontinuing use of the ENG-implant was bothersome uterine bleeding, while for SARC methods it was for personal reasons.
(© 2024 International Federation of Gynecology and Obstetrics.)
References: United Nations Population Fund. Family planning. 2022. Nearly half of all pregnancies are unintended—a global crisis. Accessed July 08, 2023. https://www.unfpa.org/press/nearly‐half‐all‐pregnancies‐are‐unintended‐global‐crisis‐says‐new‐unfpa‐report.
Bellizzi S, Mannava P, Nagai M, Sobel HL. Reasons for discontinuation of contraception among women with a current unintended pregnancy in 36 low and middle‐income countries. Contraception. 2020;101(1):26‐33.
Jones RK, Darroch JE, Henshaw SK. Contraceptive use among U.S. women having abortions in 2000‐2001. Perspect Sex Reprod Health. 2002;34(6):294‐303.
Dehlendorf C, Krajewski C, Borrero S. Contraceptive counseling: best practices to ensure quality communication and enable effective contraceptive use. Clin Obstet Gynecol. 2014;57(4):659‐673.
Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Preventing unintended pregnancy: the contraceptive CHOICE project in review. J Womens Health (Larchmt). 2015;24(5):349‐353.
Castro MC, Massuda A, Almeida G, et al. Brazil's unified health system: the first 30 years and prospects for the future. Lancet. 2019;394(10195):345‐356.
Itriyeva K. Use of long‐acting reversible contraception (LARC) and the Depo‐Provera shot in adolescents. Curr Probl Pediatr Adolesc Health Care. 2018;48(12):321‐332.
Ministério da Saúde. Pesquisa Nacional de Demografia e Saúde da Criança e da Mulher ‐ PNDS 2006. Ministério da Saúde; 2009. Accessed August 21, 2023. https://bvsms.saude.gov.br/bvs/publicacoes/pnds_crianca_mulher.pdf.
Ministério da Saúde. CONITEC. Implante subdérmico de etonogestrel na prevenção da gravidez não planejada por mulheres adultas em idade reprodutiva entre 18 e 49 anos. 2021. Accessed August 21, 2023. https://www.gov.br/conitec/pt‐br/midias/consultas/relatorios/2021/Sociedade/20210428_resoc232_etonogestrel.pdf.
Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long‐acting reversible contraception. N Engl J Med. 2012;366(21):1998‐2007.
McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration approved duration. Am J Obstet Gynecol. 2017;216(6):586.e1‐586.e6.
Bahamondes L, Brache V, Meirik O, et al. A 3‐year multicentre randomized controlled trial of etonogestrel‐ and levonorgestrel‐releasing contraceptive implants, with non‐randomized matched copper‐intrauterine device controls. Hum Reprod. 2015;30(11):2527‐2538.
Brandão ER. Métodos contraceptivos reversíveis de longa duração no Sistema Único de Saúde: O debate sobre a (in)disciplina da mulher. Ciênc Saúde Colet. 2019;24(3):875‐879.
Jamieson S. Likert scales: how to (ab) use them. Med Educ. 2004;38:1217‐1218.
The SAS System for Windows (Statistical Analysis System), version 9.4. SAS Institute Inc; 2002‐2012.
Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105‐1113.
Akilimali PZ, Hernandez J, Anglewicz P, Kayembe KP, Bertrand J. Incidence and determinants of Implanon discontinuation: findings from a prospective cohort study in three health zones in Kinshasa, DRC. PLoS One. 2020;15(5):e0232582.
Siyoum M, Mulaw Z, Abuhay M, Kebebe H. Implanon discontinuation rate and associated factors among women who ever used Implanon in the last three years in Debre Markos Town, Northwest Ethiopia, 2016, cross sectional study. ARC J Public Health Community Med. 2017;2(1):8‐16.
Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception. 2009;80(6):527‐532.
Bayer Brazil. Gravidez não planejada atinge 62% das mulheres no Brasil. 2022. (Accessed August 21, 2023). Available from: https://www.bayer.com.br/pt/blog/gravidez‐nao‐planejada‐atinge‐62‐mulheres‐brasil.
Zheng W, Tang Y, Wang C, Niu X, Qian Z, Huang L. Three‐year observational study of immediate post‐abortion insertion versus menstrual insertion of etonogestrel contraceptive implant. BMC Womens Health. 2021;21(1):436.
World Health Organization. Medical Eligibility Criteria for Contraceptive Use. Reproductive Health and Research. World Health Organization; 2015. (Accessed August 16, 2023). https://www.who.int/publications/i/item/9789241549158.
International Federation of Gynecology and Obstetrics. The benefits of Long‐Acting Reversible Contraception. (Accessed August 21, 2023). https://www.figo.org/benefits‐long‐acting‐reversible‐contraception.
Committee on Adolescent Health Care Long‐Acting Reversible Contraception Working Group, The American College of Obstetricians. Committee opinion no 539: adolescents and long‐acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2012;120(4):983‐988.
Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14‐21.
Processing Request
No Comments.